Cargando…

Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India

Background: With substantial challenges in molecular analysis of 21 hydroxylase deficiency and lack of studies in extended panel of genes implicated in CAH, genetic diagnosis is largely unavailable and unaffordable in India. Therefore, we aim to develop a cost-effective screening strategy in CAH usi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravichandran, Lavanya, Korula, Sophy, Asha, H S, Varghese, Deny, Parthiban, R, Jabasteen, J, Jebasingh, Felix, Kapoor, Nitin, Cherian, Kripa Elizabeth, Mathai, Sarah, Simon, Anna, Paul, Thomas V, Thomas, Nihal, Chapla, Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090757/
http://dx.doi.org/10.1210/jendso/bvab048.1020
_version_ 1783687360327712768
author Ravichandran, Lavanya
Korula, Sophy
Asha, H S
Varghese, Deny
Parthiban, R
Jabasteen, J
Jebasingh, Felix
Kapoor, Nitin
Cherian, Kripa Elizabeth
Mathai, Sarah
Simon, Anna
Paul, Thomas V
Thomas, Nihal
Chapla, Aaron
author_facet Ravichandran, Lavanya
Korula, Sophy
Asha, H S
Varghese, Deny
Parthiban, R
Jabasteen, J
Jebasingh, Felix
Kapoor, Nitin
Cherian, Kripa Elizabeth
Mathai, Sarah
Simon, Anna
Paul, Thomas V
Thomas, Nihal
Chapla, Aaron
author_sort Ravichandran, Lavanya
collection PubMed
description Background: With substantial challenges in molecular analysis of 21 hydroxylase deficiency and lack of studies in extended panel of genes implicated in CAH, genetic diagnosis is largely unavailable and unaffordable in India. Therefore, we aim to develop a cost-effective screening strategy in CAH using Allele Specific PCR and Targeted Next-Generation Sequencing (NGS). Methods: Long range PCR and restriction digestion were utilized to specifically amplify the CYP21A2 gene whereas multiplex PCR was used to amplify CYP11B1, CYP17A1, CYP19A1 and POR genes. In house developed Allele Specific PCR (ASPCR) for 8 hotspot mutations in CYP21A2 gene and targeted NGS for five genes was carried out. The results were validated using Sanger sequencing and MLPA. Results: Of the 50 patients suspected for 21 hydroxylase deficiency, 64% (n=32) were of Salt Wasting phenotype (SW), 30% (n=15) with Simple Virilizing (SV) phenotype and 6% (n=3) of the study population were suspected for non-classical (NC) CAH. The mutation positive rate of ASPCR was 86% (n=43). Seven patients carried more than two biallelic mutations indicating smaller gene conversions. The predominant mutation identified among the study subjects was I2G splice variant in SW phenotype (38%) and I172N in the SV phenotype (41%). Based on the Long range PCR amplification and restriction digestion we identified one patient with large gene conversion and one patient with large 30kb deletion. These results were confirmed with MLPA. Additionally, utilizing the Targeted NGS we identified five patients with CYP21A2 variants (two patients with novel variants c.1274G>T, c.17_18delTG and two other variants in three patients - c.1451G>C, c.143A>G). We also identified a CYP19A1:c.1142A>T gene variant in a patient who was initially suspected for 21 hydroxylase deficiency. Out of six patients with 11 beta hydroxylase deficiency four patients were positive for homozygous CYP11B1 variants (c.1201-1G>A, c.1200 + 1delG, c.412C>T) and two patients with compound heterozygous variants (c.1024C>T and c.1012dupC, c.623G>A and c.412C>T). Discussion: Utilizing the novel allele specific PCR followed by NGS we identified a total of 96% (48/50) of 21 hydroxylase deficiency patients with homozygous or compound heterozygous mutations and 2% (2/50) were positive for single heterozygous variant in CYP21A2 gene. ASPCR followed by multigene targeted NGS assay for genetic screening in CAH has shown to be a sensitive and specific strategy established in a clinical setting. To best of our knowledge this is the most cost-effective and comprehensive multigene screening carried out in India.
format Online
Article
Text
id pubmed-8090757
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-80907572021-05-12 Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India Ravichandran, Lavanya Korula, Sophy Asha, H S Varghese, Deny Parthiban, R Jabasteen, J Jebasingh, Felix Kapoor, Nitin Cherian, Kripa Elizabeth Mathai, Sarah Simon, Anna Paul, Thomas V Thomas, Nihal Chapla, Aaron J Endocr Soc Genetics and Development (including Gene Regulation) Background: With substantial challenges in molecular analysis of 21 hydroxylase deficiency and lack of studies in extended panel of genes implicated in CAH, genetic diagnosis is largely unavailable and unaffordable in India. Therefore, we aim to develop a cost-effective screening strategy in CAH using Allele Specific PCR and Targeted Next-Generation Sequencing (NGS). Methods: Long range PCR and restriction digestion were utilized to specifically amplify the CYP21A2 gene whereas multiplex PCR was used to amplify CYP11B1, CYP17A1, CYP19A1 and POR genes. In house developed Allele Specific PCR (ASPCR) for 8 hotspot mutations in CYP21A2 gene and targeted NGS for five genes was carried out. The results were validated using Sanger sequencing and MLPA. Results: Of the 50 patients suspected for 21 hydroxylase deficiency, 64% (n=32) were of Salt Wasting phenotype (SW), 30% (n=15) with Simple Virilizing (SV) phenotype and 6% (n=3) of the study population were suspected for non-classical (NC) CAH. The mutation positive rate of ASPCR was 86% (n=43). Seven patients carried more than two biallelic mutations indicating smaller gene conversions. The predominant mutation identified among the study subjects was I2G splice variant in SW phenotype (38%) and I172N in the SV phenotype (41%). Based on the Long range PCR amplification and restriction digestion we identified one patient with large gene conversion and one patient with large 30kb deletion. These results were confirmed with MLPA. Additionally, utilizing the Targeted NGS we identified five patients with CYP21A2 variants (two patients with novel variants c.1274G>T, c.17_18delTG and two other variants in three patients - c.1451G>C, c.143A>G). We also identified a CYP19A1:c.1142A>T gene variant in a patient who was initially suspected for 21 hydroxylase deficiency. Out of six patients with 11 beta hydroxylase deficiency four patients were positive for homozygous CYP11B1 variants (c.1201-1G>A, c.1200 + 1delG, c.412C>T) and two patients with compound heterozygous variants (c.1024C>T and c.1012dupC, c.623G>A and c.412C>T). Discussion: Utilizing the novel allele specific PCR followed by NGS we identified a total of 96% (48/50) of 21 hydroxylase deficiency patients with homozygous or compound heterozygous mutations and 2% (2/50) were positive for single heterozygous variant in CYP21A2 gene. ASPCR followed by multigene targeted NGS assay for genetic screening in CAH has shown to be a sensitive and specific strategy established in a clinical setting. To best of our knowledge this is the most cost-effective and comprehensive multigene screening carried out in India. Oxford University Press 2021-05-03 /pmc/articles/PMC8090757/ http://dx.doi.org/10.1210/jendso/bvab048.1020 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Genetics and Development (including Gene Regulation)
Ravichandran, Lavanya
Korula, Sophy
Asha, H S
Varghese, Deny
Parthiban, R
Jabasteen, J
Jebasingh, Felix
Kapoor, Nitin
Cherian, Kripa Elizabeth
Mathai, Sarah
Simon, Anna
Paul, Thomas V
Thomas, Nihal
Chapla, Aaron
Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India
title Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India
title_full Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India
title_fullStr Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India
title_full_unstemmed Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India
title_short Comprehensive and Cost-Effective Strategy for Genetic Screening of Congenital Adrenal Hyperplasia (CAH) in India
title_sort comprehensive and cost-effective strategy for genetic screening of congenital adrenal hyperplasia (cah) in india
topic Genetics and Development (including Gene Regulation)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090757/
http://dx.doi.org/10.1210/jendso/bvab048.1020
work_keys_str_mv AT ravichandranlavanya comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT korulasophy comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT ashahs comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT varghesedeny comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT parthibanr comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT jabasteenj comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT jebasinghfelix comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT kapoornitin comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT cheriankripaelizabeth comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT mathaisarah comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT simonanna comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT paulthomasv comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT thomasnihal comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia
AT chaplaaaron comprehensiveandcosteffectivestrategyforgeneticscreeningofcongenitaladrenalhyperplasiacahinindia